Venetian Hotel
Casanova Rooms 503-505
Las Vegas, NV

PROGRAM DESCRIPTION

Despite the advances in acute and chronic treatment of acute coronary syndrome (ACS) patients, there is still considerable uncertainty among pharmacists about the relative benefit of various antiplatelet agents in protecting against ischemic complications from ACS and PCI. Understanding the subtle differences between available and emerging agents for preventing thrombotic events, including their relative risks for bleeding complications, is essential to improve the management of ACS patients.

This program will examine the importance of acute and long-term antiplatelet therapy to protect UA/NSTEMI patients against thrombotic events. Health-system pharmacists will gain insights into preferred clinical practices based on established treatment guidelines; pivotal evidence-based clinical trial results; and recommended dosings and length of treatment for the various antiplatelet agents.

Faculty

	Sarah Spinler, PharmD, FAHA, FCCP, BCPS (AQ Cardiology)—Chair Professor of Clinical Pharmacy Residency and Fellowship Program Coordinator Philadelphia College of Pharmacy University of the Sciences in Philadelphia Philadelphia, PA
	David S. Roffman, PharmD, BCPS (AQ Cardiology) Associate Dean for Academic Affairs Professor, Pharmacy Practice and Science School of Pharmacy, University of Maryland Therapeutic Consultant, Cardiology University of Maryland Medical Center Baltimore, MD
	Sandeep Nathan, MD, MSc, FACC, FSCAI Assistant Professor of Medicine Director, Interventional Cardiology Fellowship Program University of Chicago Medical Center Chicago, IL

AGENDA

5:30–6:00 PM: Registration and Dinner

6:00–7:45 PM: CE Program

1. Pathophysiology and Clinical Presentations of ACS -
   Sandeep Nathan, MD, MSc, FACC, FSCAI
   • Pivotal role of the platelet in thromboembolism and ACS
   • Identification of patients at risk of UA/NSTEMI
   • Initial evaluation and management


2. UA/NSTEMI: Early Hospital Care with Antiplatelet Therapy -
   Sarah Spinler, PharmD, FAHA, FCCP, BCPS
   • ACC/AHA treatment guidelines for early hospital care in UA/NSTEMI
   • Rationale for treatments


3. Post-ACS and Post-PCI Antiplatelet Therapy: Balancing Efficacy and Bleeding Risk -
   David S. Roffman, PharmD, BCPS
   • 2007 ACC/AHA treatment guidelines for use of oral antiplatelet agents post-ACS
   • Dual antiplatelet therapy is standard practice for post-PCI patients
   • Considerations of current therapies

7:45–8:00 PM: Question and Answer Session

TARGET AUDIENCE

This program was developed for health-system pharmacists.

EDUCATIONAL OBJECTIVES

This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to:

1. Explain the role of the platelet in thromboembolism and the mechanisms by which the various antiplatelet agents protect against thromboembolic events
2. Recommend appropriate antiplatelet therapy for a patient with NSTEMI scheduled for PCI, and as recommended by the ACC/AHA treatment guidelines
3. Compare current and emerging oral antiplatelet strategies for long-term protection against risk of thromboembolic events in ACS patients, including recommended dose and duration of therapy

ELIGIBILITY

In order to attend this satellite symposium, an individual must be registered to attend the 44th ASHP Midyear Clinical Meeting and Exhibition.

ACCREDITATION

The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing medical education.

CREDIT DESIGNATION

The Potomac Center for Medical Education designates this educational activity for a maximum of 2.0 hours (0.2 CEUs) of continuing education credit (program number 418-000-09-001-L01-P). Participants will receive statement of credit (within four to six weeks) after attending the activity and completing an activity evaluation form.

Activity Type Application-based CPE activity

DISCLOSURE POLICY

Potomac Center for Medical Education (PCME) adheres to the guidelines of Accreditation Council for Pharmacy Education (ACPE) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All faculty in a position to control the content of a continuing education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest. All conflicts are identified and resolved by PCME in advance of delivery of the activity to learners. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

The content of this activity was vetted by an external pharmacy reviewer to assure objectivity and that the activity is free of commercial bias.

FDA Disclosure

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

SPECIAL SERVICES

Event staff will be glad to assist you with any special needs (e.g. physical, dietary). Please email specialservices@potomacme.org at least five days prior to the program.

 

This program is supported through an educational grant from

Sponsored by:

By clicking this button you are agreeing that you have read and understood the CE Statements above.